Applications of 2-Fluoro-5-Formylphenylboronic Acid in Industrial Manufacturing

2-Fluoro-5-formylphenylboronic acid functions as a key intermediate in advanced chemical synthesis, supporting the manufacture of high-value specialty and pharmaceutical compounds. Our facility delivers this boronic acid directly to various global industries, aligning with strict regulatory requirements and technical specifications.

1. API Intermediate in Oncology Drug Synthesis

2-Fluoro-5-formylphenylboronic acid is widely used by pharmaceutical manufacturers as a building block in the synthesis of molecularly targeted oncology APIs, including kinase inhibitors. Its specific fluorinated and formyl functional groups facilitate efficient Suzuki-Miyaura cross-coupling reactions, crucial for constructing biaryl motifs in late-stage process development. Our expertise ensures consistent supply supporting stringent regulatory filings and GMP process flows.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• FDA 21 CFR 210/211 Compliance
• EU GMP Part II (APIs)
• Synthetic process development per EMA/CHMP/QWP/130/96

Typical usage ratio

• Applied at 0.05 to 0.2 molar equivalents relative to key aryl halide components
• Adjusted according to desired coupling efficiency and impurity profile management

Downstream process integration

• Introduced after the preparation of halogenated aromatic precursors
• Used under inert atmosphere during the palladium-catalyzed cross-coupling stage
• Integrated with inline HPLC or GC monitoring to control residual boronic acid

Final product types

• Small molecule kinase inhibitors for oncological indications
• Molecular scaffolds for further API diversification

2. Fine Chemical Intermediate for Agrochemical Synthesis

Manufacturers in the crop protection sector utilize this boronic acid to construct fluorinated agrochemical actives, particularly in herbicide and fungicide programs requiring a stable aromatic core. Its unique reactivity under mild conditions reduces byproduct formation and enables precise structural modification demanded by modern agrochemical research and development chains.

Industry compliance standards

• ISO 9001:2015 Quality Management
• REACH Regulation (EC) No 1907/2006 Registration
• FAO/WHO Good Laboratory Practice (GLP) for registration data

Typical usage ratio

• 0.08–0.25 molar equivalents in biaryl or diaryl ether-forming reactions
• Optimized for target yield and minimization of environmentally persistent residues

Downstream process integration

• Added after halogenated precursor generation in multi-step synthesis
• Reacted in the presence of aqueous base and palladium catalysts
• Coupled with downstream purification to meet regulatory impurity thresholds

Final product types

• Fluorinated herbicide pre-formulations
• Advanced fungicidal intermediates

3. OLED Material Intermediate for Electronic Chemicals

The electronics industry applies this compound in the synthesis of boron-based building blocks for organic light-emitting diode (OLED) emitters and hole-transport materials. Its precise regiochemistry and high purity contribute to reliable device performance and enable formation of advanced conjugated structures with customized optoelectronic properties. Production adheres to electronic grade quality controls to ensure product integration into downstream vacuum deposition processes.

Industry compliance standards

• IEC 60747-5 Semiconductor Device Process Control
• RoHS Directive (EU 2011/65)
• ISO 9001:2015 for Electronic Chemical Manufacturing

Typical usage ratio

• 0.1 to 0.25 molar equivalents, controlled for minimal functional group excess
• Adjusted based on target molecular weight and polymer end-group control

Downstream process integration

• Incorporated during the Suzuki coupling phase of poly(p-phenylene) or aromatic monomer synthesis
• Employed under water-free conditions to minimize moisture-sensitive side reactions
• Final product typically undergoes sublimation purification for device usage

Final product types

• Blue, green, and red OLED emitter molecules
• Hole-transport layers and charge-transport materials

4. Fluorinated Ligand Synthesis for Catalysis Research

Research organizations and catalyst manufacturers use this compound to synthesize fluorinated biphenyl ligands, which serve as specialized ligands for organometallic catalytic systems. Its dual-function reactivity provides critical positional selectivity, supporting catalyst libraries for cross-coupling and C-H activation applications in both research laboratories and pilot-scale development suites.

Industry compliance standards

• GLP Compliance for Catalyst Synthesis (OECD Principles)
• ISO/IEC 17025 Accreditation for Laboratory Production
• Internal customer-specific quality protocols based on end-use

Typical usage ratio

• 1.0 equivalent as a starting monomer for ligand generation
• May be adjusted for structure-activity relationship (SAR) screening needs

Downstream process integration

• Used as a substrate for Suzuki or other cross-coupling with phosphine or nitrogen donor aryl partners
• Product purified by column chromatography or crystallization prior to catalyst complexation
• Batch or semi-batch reactor configuration depending on scale

Final product types

• Fluorinated biphenyl ligands for Pd and Ni catalysis
• Specialty ligand panels for catalyst screening kits

5. Synthesis of Diagnostic Radiopharmaceutical Precursors

Developers of diagnostic imaging agents utilize this compound to introduce fluorinated motifs into molecular tracers designed for radiofluorination. Its formyl functionality allows late-stage derivatization, providing a precursor for complex ^18F-tagged molecules in PET radiopharmaceutical development workflows, in compliance with specific standards for radiochemical purity, sterility, and traceability.

Industry compliance standards

• Ph. Eur. General Monograph 0125 (Radiopharmaceutical Preparation)
• USP <823> Positron Emission Tomography Drugs
• GMP for Radiopharmaceuticals (PIC/S PE 010-4)

Typical usage ratio

• 0.05–0.15 molar equivalents as a late-stage functionalizing agent
• Adjusted based on required radiochemical yield and labeling efficiency

Downstream process integration

• Reacted with nucleophilic or electrophilic radiolabeling agents after protection/deprotection stages
• Synthesized under aseptic or shielded conditions to prevent radioactive contamination
• Integrated with SPE purification and QC per radiopharmacy workflows

Final product types

• ^18F-labeled PET tracer precursor molecules
• Radiopharmaceutical intermediates for preclinical and clinical imaging